Gilead Sciences, Inc.
NASDAQ:GILDDrug Manufacturers - General
-$2.69 today
- Market cap
- $209.59B
- Beta
- 0.33
- P/E (TTM)
- 16.5
- EPS (TTM)
- $7.42
- Dividend yield
- 2.62%
Volume 4.82M
Average 6.78M
GILD Total Liabilities
Everything the company owes to creditors and other parties.
Gilead Sciences, Inc.NASDAQ: GILD
Total Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total liabilities rises 4.1% from a year ago
Total liabilities stood at $37.62B at the end of Q2 FY2026, up 4.1% from a year earlier and up 14.5% from the prior quarter. Over 3 fiscal years it compounded at -4.6% a year.
Context
- Total liabilities amounted to 76.2% of total assets at the end of Q2 FY2026, up 11.4 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +4.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 36.41B USD
- Year-over-year change
- -8.4%
- 4-year CAGR
- -6.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.41B | -8.4% |
| FY2024 | 2024-12-31 | 39.75B | +0.9% |
| FY2023 | 2023-12-31 | 39.38B | -6.2% |
| FY2022 | 2022-12-31 | 41.96B | -10.5% |
| FY2021 | 2021-12-31 | 46.89B | — |
Total Liabilities vs competitors
How GILD compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +4.1% is the 5th highest of 10, against a peer median of +2.7%.
- Total liabilities amounts to 76.2% of total assets for GILD, versus a peer median of 65.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $141B USD | +2.7% | +4.1% | 104.3% | |
| Sep 2026 | $115.9B USD | +2.1% | +2.1% | 58.7% | |
| Jun 2026 | $115.64B USD | -1.2% | +6.2% | 57.5% | |
| Jun 2026 | $108.4B USD | +31.3% | +30.4% | 76.2% | |
| Jun 2026 | $87.82B USD | +28.3% | +10.1% | 67.7% | |
| Jun 2026 | $80.09B USD | +28.5% | +6.0% | 65.6% | |
| Sep 2026 | $67.99B USD | -0.7% | +3.2% | 56.8% | |
| Jun 2026 | €59.49B EUR | +8.8% | +2.2% | 46.1% | |
| Jun 2026 | £44.29B GBP | -28.0% | -3.5% | 72.2% | |
| Jun 2026 | $37.62B USD | +4.1% | -4.6% | 76.2% | |
| Peer median (excluding GILD) | — | +2.7% | +4.1% | 65.6% | |
Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.34B | 5.41B | 6.09B | 9.99B | 7.56B |
| Short-term Investments | 1.18B | 973M | 1.18B | 1.58B | 2.05B |
| Net Receivables | 4.49B | 4.78B | 4.66B | 4.42B | 4.91B |
| Inventory | 1.62B | 1.51B | 1.79B | 1.71B | 1.77B |
| Other Current Assets | 0 | 0 | 2.37B | 995M | 1.14B |
| Total Current Assets | 14.77B | 14.44B | 16.09B | 19.17B | 18.34B |
| Property, Plant & Equipment (Net) | 5.12B | 5.48B | 5.32B | 5.41B | 5.61B |
| Goodwill | 8.33B | 8.31B | 8.31B | 8.31B | 8.31B |
| Intangible Assets | 33.46B | 28.89B | 26.45B | 19.95B | 16.98B |
| Long-term Investments | 1.31B | 1.25B | 1.16B | 0 | 2.97B |
| Tax Assets | 0 | 0 | 0 | 2.38B | 1.96B |
| Other Non-current Assets | 4.96B | 4.8B | 4.79B | 3.77B | 4.85B |
| Total Non-current Assets | 53.18B | 48.73B | 46.04B | 39.82B | 40.68B |
| Total Assets | 67.95B | 63.17B | 62.13B | 59B | 59.02B |
| Account Payables | 705M | 905M | 550M | 833M | 715M |
| Short-term Debt | 1.52B | 2.27B | 1.8B | 1.82B | 2.81B |
| Tax Payables | 539M | 959M | 1.21B | 830M | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.43B | 3.62B | 3.92B | 3.82B | 3.86B |
| Total Current Liabilities | 11.61B | 11.24B | 11.28B | 12B | 11.81B |
| Long-term Debt | 25.18B | 22.96B | 23.19B | 24.9B | 22.13B |
| Deferred Tax Liabilities | 4.36B | 2.67B | 1.59B | 724M | 402M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.74B | 5.09B | 3.32B | 2.13B | 2.06B |
| Total Non-current Liabilities | 35.28B | 30.72B | 28.1B | 27.75B | 24.59B |
| Total Liabilities | 46.89B | 41.96B | 39.38B | 39.75B | 36.41B |
| Common Stock | 1M | 1M | 1M | 1M | 1M |
| Retained Earnings | 16.32B | 15.69B | 16.3B | 11.5B | 13.73B |
| Accumulated OCI | 83M | 2M | 28M | 132M | 39M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (5M) | (31M) | (84M) | (84M) | (84M) |
| Total Equity | 21.06B | 21.21B | 22.75B | 19.25B | 22.62B |
| Total Debt | 26.7B | 25.23B | 24.99B | 26.71B | 24.94B |
| Net Debt | 21.36B | 19.82B | 18.9B | 16.72B | 17.37B |
Gilead Sciences, Inc.
NASDAQ:GILD
Intrinsic Alpha fair value
Locked
Current Price
$168.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.